Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LIPE | Q05469 | 1/20 | 0.39 |
| ▸ | HSD17B1 | P14061 | 9/20 | 0.38 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.36 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | HSD17B2 | P37059 | 8/20 | 0.33 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | APAF1 | O14727 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | TDP2 | O95551 | 1/20 | 0.32 |
| ▸ | NSD2 | O96028 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | CASP3 | P42574 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19712384 | 0.86 | DDB1 (0.36) | GPBAR1ALDH1A1SMN1; SMN2TP53KMT2A | |
| SCHEMBL9960567 | 0.85 | LIPE (0.41) | LIPEGPBAR1ALDH1A1PIK3CAAPAF1 | |
| SCHEMBL9960496 | 0.83 | RAB9A (0.46) | LIPEALDH1A1LMNASMN1; SMN2NPC1 | |
| SCHEMBL9960629 | 0.82 | RAB9A (0.42) | ALDH1A1LMNANPC1RAB9AKMT2A | |
| SCHEMBL9960651 | 0.79 | HSD17B1 (0.41) | LIPEHSD17B1SIGMAR1GPBAR1ALDH1A1 | |
| SCHEMBL9960807 | 0.79 | LMNA (0.47) | LIPEGPBAR1LMNAMAPTSMN1; SMN2 | |
| SCHEMBL9960717 | 0.79 | RAB9A (0.36) | GPBAR1ALDH1A1PIK3CALMNAMAPT | |
| SCHEMBL9960627 | 0.76 | MAPT (0.34) | GPBAR1ALDH1A1LMNAMAPTCYP3A4 | |
| SCHEMBL9960695 | 0.76 | SLC12A5 (0.37) | ALDH1A1LMNAMAPTNPC1CYP1A2 | |
| SCHEMBL9960497 | 0.76 | ACHE (0.36) | ALDH1A1LMNAKMT2AATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2655323-B1 | INGENOL-3-ACYLATES III AND INGENOL-3-CARBAMATES | LEO LABORATORIES LTD (IE) | 2017-12-20 | — | — | EP | claimed |
| US-20170217910-A1 | INGENOL-3-ACYLATES III AND INGENOL-3-CARBAMATES | LEO LABORATORIES LIMITED (IE) | 2017-08-03 | — | — | US | claimed |
| US-9708286-B2 | Ingenol-3-acylates III and ingenol-3-carbamates | LEO LABORATORIES LIMITED (IE) | 2017-07-18 | — | — | US | claimed |
| CN-104529827-B | Ingenol-3-acylate III and ingenol-3-carbamate | 利奥实验室有限公司 | 2016-08-24 | — | — | CN | claimed |
| US-20150291551-A1 | INGENOL-3-ACYLATES III AND INGENOL-3-CARBAMATES | LEO LABORATORIES LIMITED (IE) | 2015-10-15 | — | — | US | claimed |
| CN-104529827-A | Ingenol-3-acylates III and ingenol-3-carbamates | LEO PHARMA AS | 2015-04-22 | — | — | CN | claimed |
| US-20140303150-A1 | INGENOL-3-ACYLATES III AND INGENOL-3-CARBAMATES | LEO LABORATORIES LIMITED (IE) | 2014-10-09 | — | — | US | claimed |
| CN-103402977-A | Ingenol-3-acylate III and Ingenol-3-carbamate | LEO PHARMA AS | 2013-11-20 | — | — | CN | claimed |
| EP-2655323-A1 | INGENOL-3-ACYLATES III AND INGENOL-3-CARBAMATES | LEO LABORATORIES LIMITED (IE) | 2013-10-30 | — | — | EP | claimed |
| WO-2012083953-A1 | INGENOL-3-ACYLATES III AND INGENOL-3-CARBAMATES | LEO PHARMA A/S (DK) | 2012-06-28 | — | — | WO | claimed |
| EP-2655323-B1 | INGENOL-3-ACYLATES III AND INGENOL-3-CARBAMATES | LEO LABORATORIES LTD (IE) | 2017-12-20 | — | — | EP | disclosed |
| US-20170217910-A1 | INGENOL-3-ACYLATES III AND INGENOL-3-CARBAMATES | LEO LABORATORIES LIMITED (IE) | 2017-08-03 | — | — | US | disclosed |
| US-9708286-B2 | Ingenol-3-acylates III and ingenol-3-carbamates | LEO LABORATORIES LIMITED (IE) | 2017-07-18 | — | — | US | disclosed |
| CN-104529827-B | Ingenol-3-acylate III and ingenol-3-carbamate | 利奥实验室有限公司 | 2016-08-24 | — | — | CN | disclosed |
| CN-103402977-B | Ingenol-3-acylate III and ingenol-3-carbamate | LEO PHARMA A/S (IE) | 2016-01-20 | — | — | CN | disclosed |
| US-20140303150-A1 | INGENOL-3-ACYLATES III AND INGENOL-3-CARBAMATES | LEO LABORATORIES LIMITED (IE) | 2014-10-09 | — | — | US | disclosed |
| WO-2013182688-A1 | A TOPICAL GEL COMPOSITION COMPRISING AN INGENOL DERIVATIVE AND A SOLVENT MIXTURE | LEO LABORATORIES LIMITED (IE) | 2013-12-12 | — | — | WO | disclosed |
| CN-103402977-A | Ingenol-3-acylate III and Ingenol-3-carbamate | LEO PHARMA AS | 2013-11-20 | — | — | CN | disclosed |
| EP-2655323-A1 | INGENOL-3-ACYLATES III AND INGENOL-3-CARBAMATES | LEO LABORATORIES LIMITED (IE) | 2013-10-30 | — | — | EP | disclosed |
| WO-2012083953-A1 | INGENOL-3-ACYLATES III AND INGENOL-3-CARBAMATES | LEO PHARMA A/S (DK) | 2012-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170217910-A1 | INGENOL-3-ACYLATES III AND INGENOL-3-CARBAMATES | RXRB, RXRA, RXRG | LIPE 1147/4885HSD17B1 1501/4885SIGMAR1 1187/4885 |
| US-20150291551-A1 | INGENOL-3-ACYLATES III AND INGENOL-3-CARBAMATES | RXRB, RXRA, RXRG | LIPE 1147/4885HSD17B1 1501/4885SIGMAR1 1187/4885 |
| US-20140303150-A1 | INGENOL-3-ACYLATES III AND INGENOL-3-CARBAMATES | RXRB, RXRA, RXRG | LIPE 1147/4885HSD17B1 1501/4885SIGMAR1 1187/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.